Clinical Trials Directory

Trials / Completed

CompletedNCT06168890

Predictive Role of [11C] Choline PET/CT on Survival in Prostate Cancer Patients With Biochemical Failure.

Status
Completed
Phase
Study type
Observational
Enrollment
195 (actual)
Sponsor
IRCCS San Raffaele · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers

Summary

Several studies have shown that the PET/CT study with Choline is of great use in the restaging of patients with prostate cancer who present a recurrence of biochemical disease following primary treatment. Despite the large amount of literature in which the diagnostic accuracy of the method is highlighted in the identification of the recurrence of prostatic disease both in the case of local recurrence, lymph node recurrence and metastatic disease, there are to date no studies that evaluate whether PET /CT with choline may predict survival in patients radically treated for prostate cancer. The aim of the study is to evaluate the predictive role of choline PET/CT on the survival of patients with biochemical recovery of the disease during hormonal therapy. This retrospective study will include adult patients affected by prostate cancer with biochemical recurrence of the disease following radical prostatectomy treatment and undergoing hormonal therapy who underwent, between 2004 and 2007, a PET/CT study with choline for the restaging of their disease. The expected result is to establish how PET/CT with Choline can predict survival in patients who develop a biochemical recurrence of the disease during hormonal therapy. If this result is confirmed, PET/CT with Choline could be even more useful in the follow-up of patients radically treated for prostate cancer to plan the best therapeutic approach.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTPET/CT with choline in the restaging phase of prostate cancer.PET/CT with choline in the restaging phase of prostate cancer in patients suffering from prostate cancer with biochemical recovery of the disease during hormonal therapy.

Timeline

Start date
2014-02-04
Primary completion
2014-02-25
Completion
2014-02-25
First posted
2023-12-13
Last updated
2023-12-13

Source: ClinicalTrials.gov record NCT06168890. Inclusion in this directory is not an endorsement.